Clinical investigations into the modification of the effect of endogenous and exogenous insulin by human proinsulin in type II and type I diabetics.
The investigation on hand leads to the conclusion that HPRO can additively increase the blood glucose lowering effect of endogenous and exogenously administered insulin. Etiologically the prolonged retention time of HPRO in the circulation - compared to HI - must be primarily discussed. In the further course the question arises to what extent traditional retard insulins would have to be replaced or supplemented by HPRO.
Bellenberg
S
S
Bethesda-Krankenhaus Duisburg, Germany.
Schröder
K E
KE
Schlüter
K J
KJ
Bottermann
P
P
Zilker
T
T
Gray
P
P
D000368:Aged; D001786:Blood Glucose / Q000378:metabolism; D002096:C-Peptide / Q000097:blood; D003922:Diabetes Mellitus, Type 1 / Q000097:blood / Q000188:drug therapy*; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy*; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D006801:Humans; D007328:Insulin / Q000008:administration & dosage* / Q000627:therapeutic use; D007332:Insulin Infusion Systems; D008875:Middle Aged; D011384:Proinsulin / Q000008:administration & dosage* / Q000627:therapeutic use
D001786:Blood Glucose; D002096:C-Peptide; D007328:Insulin; D011384:Proinsulin